1h Free Analyst Time
SummarySpeak directly to the analyst to clarify any post sales queries you may have.
The latest Pharmaceutical and Healthcare disease pipeline guide Kidney Fibrosis - Pipeline Review, H2 2020, provides an overview of the Kidney Fibrosis (Genito Urinary System And Sex Hormones) pipeline landscape.
Accumulation of extracellular matrix in the kidney causes kidney fibrosis. It is a progressive disorder characterized by glomerulosclerosis and tubulointerstitial fibrosis and may lead to detrimental effects on the kidney functioning. Predisposing factors are trauma, injury, infections, surgery, environmental factors and exposure to chemicals or radiation. Symptoms include pain, problems related to urination, nausea and vomiting. The condition may be managed with medication and kidney transplant.
Report Highlights
The Pharmaceutical and Healthcare latest pipeline guide Kidney Fibrosis - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Kidney Fibrosis (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Kidney Fibrosis (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Kidney Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 33 and 6 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 7 molecules, respectively.
Kidney Fibrosis (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Kidney Fibrosis (Genito Urinary System And Sex Hormones).
- The pipeline guide reviews pipeline therapeutics for Kidney Fibrosis (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Kidney Fibrosis (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Kidney Fibrosis (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Kidney Fibrosis (Genito Urinary System And Sex Hormones)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Kidney Fibrosis (Genito Urinary System And Sex Hormones).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Kidney Fibrosis (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Kidney Fibrosis - Overview
- Kidney Fibrosis - Therapeutics Development
- Kidney Fibrosis - Therapeutics Assessment
- Kidney Fibrosis - Companies Involved in Therapeutics Development
- Kidney Fibrosis - Drug Profiles
- Kidney Fibrosis - Dormant Projects
- Kidney Fibrosis - Discontinued Products
- Kidney Fibrosis - Product Development Milestones
- Appendix
List of Tables
- Number of Products under Development for Kidney Fibrosis, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Products under Development by Companies, H2 2020
- Products under Development by Universities/Institutes, H2 2020
- Number of Products by Stage and Target, H2 2020
- Number of Products by Stage and Mechanism of Action, H2 2020
- Number of Products by Stage and Route of Administration, H2 2020
- Number of Products by Stage and Molecule Type, H2 2020
- Kidney Fibrosis - Pipeline by AdAlta Ltd, H2 2020
- Kidney Fibrosis - Pipeline by Algernon Pharmaceuticals Inc, H2 2020
- Kidney Fibrosis - Pipeline by Angion Biomedica Corp, H2 2020
- Kidney Fibrosis - Pipeline by AstraZeneca Plc, H2 2020
- Kidney Fibrosis - Pipeline by BiOrion Technologies BV, H2 2020
- Kidney Fibrosis - Pipeline by Blade Therapeutics Inc, H2 2020
- Kidney Fibrosis - Pipeline by Cellmid Ltd, H2 2020
- Kidney Fibrosis - Pipeline by Curacle Co Ltd, H2 2020
- Kidney Fibrosis - Pipeline by Epigen Biosciences Inc, H2 2020
- Kidney Fibrosis - Pipeline by Evotec SE, H2 2020
- Kidney Fibrosis - Pipeline by Future Medicine Co Ltd, H2 2020
- Kidney Fibrosis - Pipeline by Galapagos NV, H2 2020
- Kidney Fibrosis - Pipeline by Galectin Therapeutics Inc, H2 2020
- Kidney Fibrosis - Pipeline by GenKyoTex SA, H2 2020
- Kidney Fibrosis - Pipeline by Hepion Pharmaceuticals Inc, H2 2020
- Kidney Fibrosis - Pipeline by iBio Inc, H2 2020
- Kidney Fibrosis - Pipeline by Isarna Therapeutics GmbH, H2 2020
- Kidney Fibrosis - Dormant Projects, H2 2020
- Kidney Fibrosis - Discontinued Products, H2 2020
List of Figures
- Number of Products under Development for Kidney Fibrosis, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products by Top 10 Targets, H2 2020
- Number of Products by Stage and Top 10 Targets, H2 2020
- Number of Products by Top 10 Mechanism of Actions, H2 2020
- Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
- Number of Products by Routes of Administration, H2 2020
- Number of Products by Stage and Routes of Administration, H2 2020
- Number of Products by Top 10 Molecule Types, H2 2020
- Number of Products by Stage and Top 10 Molecule Types, H2 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AdAlta Ltd
- Algernon Pharmaceuticals Inc
- Angion Biomedica Corp
- AstraZeneca Plc
- BiOrion Technologies BV
- Blade Therapeutics Inc
- Cellmid Ltd
- Curacle Co Ltd
- Epigen Biosciences Inc
- Evotec SE
- Future Medicine Co Ltd
- Galapagos NV
- Galectin Therapeutics Inc
- GenKyoTex SA
- Hepion Pharmaceuticals Inc
- iBio Inc
- Isarna Therapeutics GmbH
- Kadmon Corp LLC
- Liminal BioSciences Inc
- Max Biopharma Inc
- Mission Therapeutics Ltd
- NB Health Laboratory Co Ltd
- Novo Nordisk AS
- Osteoneurogen Inc
- Pharmaxis Ltd
- Sanofi
- Scholar Rock Inc
- Senolytic Therapeutics Inc
- TiumBio Co Ltd
- TRACON Pharmaceuticals Inc
- Transcenta Holding Ltd
- Vascular Biogenics Ltd
- Vectus Biosystems Ltd
